Olmesartan in Management of Proteinuria

Journal Title: Journal of Clinical and Diagnostic Research - Year 2018, Vol 12, Issue 2

Abstract

ABSTRACT Proteinuria is a marker and predictor of cardiovascular morbidity and mortality. Blockade of angiotensin receptor might result in reduction in proteinuria. Olmesartan, an Angiotensin Receptor Blocker (ARB) which is approved for the treatment of hypertension is believed to produce antiproteinuric effects through different mechanisms. The objective of this review is to assess the cause, duration and degree of proteinuria and understand the current place of olmesartan in management of proteinuria associated with Cardiovascular Disease(CVD) and hypertension. We performed a comprehensive search of MEDLINE, PubMed and Google Scholar databases for articles related to Olmesartan and proteinuria (till June 2017). Angiotensin-II induces transforming growth factor-β upregulation and increase transcapillary pressure. AT-I receptor blocked by olmesartan result in reduction in proteinuria. Olmesartan significantly reduces Blood Pressure (BP) and delays the onset of Chronic Kidney Disease (CKD), it also delayed the risk of onset of microalbuminuria. Olmesartan have nephroprotective, antioxidant, antifibrotic activities and proteinuria reducing effects which can be beneficial in patients with hypertension. Olmesartanis believed to produce antiproteinuric effects through different mechanisms. It is indicated for treatment of hypertension to reduce the risk of fatal and non fatal CV events which may or may not be associated with proteinuria.

Authors and Affiliations

Satyanarayan Routray, VN Shah, Abhay Sahoo, Priti Sanghavi, Amit Omprakash Gupta, Onkar C Swami

Keywords

Related Articles

Syndrome of Inappropriate Secretion of Antidiuretic Hormone Preceding Guillain-Barré Syndrome

Guillain–Barré Syndrome (GBS) is an inflammatory polyradiculoneuropathy which is known to produce syndrome of inappropriate Secretion of Antidiuretic Hormone (SIADH). However, the hyponatremia is usually seen after the o...

Unusually High Serum Levels of CA 19-9 in an Ovarian Tumour: Malignant or Benign?

Carbohydrate antigen 19-9 (CA 19-9) is a tumour marker found to be elevated in some ovarian tumours. We share our experience with a 55-year-old postmenopausal lady with unusually high CA19-9 levels arising from a benign...

Immunohistochemical Study of ER, PR, Ki67 and p53 in Endometrial Hyperplasias and Endometrial Carcinomas

Introduction: Endometrial carcinoma is the second most common gynecologic malignancy in the developing countries. Endometrial Hyperplasia (EH) is a precursor to Endometrioid Adenocarcinoma (EMAC). A 23% of Atypical Hyper...

Effect of Yoga and Physical Exercise on Motor Functions among Substance Abusers: A Randomised Comparative Study

ABSTRACT Introduction: Substance abuse disorder is characterised by severe motor function impairment. Rehabilitation programs should augment the motor function to reduce the risk of relapse. Yoga and exercise-based inte...

Cytological Study of Abdominal Lymph Nodes by Fine Needle Aspiration under Image Guidance

ABSTRACT Introduction: Fine Needle Aspiration Cytology (FNAC) has become simple, safe, speedy, cost-effective, accurate and more diagnostic after advancement in imaging techniques. Sensitivity of image guided FNAC of int...

Download PDF file
  • EP ID EP519622
  • DOI 10.7860/JCDR/2018/32522.11199
  • Views 51
  • Downloads 0

How To Cite

Satyanarayan Routray, VN Shah, Abhay Sahoo, Priti Sanghavi, Amit Omprakash Gupta, Onkar C Swami (2018). Olmesartan in Management of Proteinuria. Journal of Clinical and Diagnostic Research, 12(2), 1-5. https://europub.co.uk/articles/-A-519622